Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 02, 2022

BUY
$11.82 - $15.42 $496,203 - $647,331
41,980 New
41,980 $538,000
Q2 2022

Aug 01, 2022

SELL
$7.31 - $13.55 $218,788 - $405,551
-29,930 Closed
0 $0
Q1 2022

May 04, 2022

SELL
$10.47 - $16.75 $9,318 - $14,907
-890 Reduced 2.89%
29,930 $313,000
Q4 2021

Feb 07, 2022

SELL
$15.36 - $25.0 $21,964 - $35,750
-1,430 Reduced 4.43%
30,820 $476,000
Q3 2021

Nov 02, 2021

SELL
$22.56 - $29.68 $6,091 - $8,013
-270 Reduced 0.83%
32,250 $728,000
Q2 2021

Aug 03, 2021

SELL
$24.96 - $41.25 $53,664 - $88,687
-2,150 Reduced 6.2%
32,520 $837,000
Q1 2021

May 04, 2021

BUY
$28.0 - $53.42 $970,760 - $1.85 Million
34,670 New
34,670 $1.45 Million

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $613M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.